Genetic reprogramming of bacterial biofilms
US-2020255480-A1 · Aug 13, 2020 · US
US11098133B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11098133-B2 |
| Application number | US-201716302687-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 19, 2017 |
| Priority date | May 19, 2016 |
| Publication date | Aug 24, 2021 |
| Grant date | Aug 24, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are compositions and methods of making hydrogels, aerogels, films and composites directly from a microbial culture or complex mixture using curli nanofibers.
Opening claim text (preview).
The invention claimed is: 1. A biologic hydrogel comprising a curli fiber and a surfactant, wherein the hydrogel comprises at least 3% (w/w) curli fiber, wherein the curli fiber comprises a wild-type CsgA or an engineered CsgA fusion protein, and wherein the engineered CsgA fusion protein comprises a CsgA polypeptide fused to an activity polypeptide. 2. The biologic hydrogel of claim 1 , wherein the activity polypeptide is a mucoadhesive polypeptide, a porin, a ribosomal protein or a plastocyanin. 3. The biologic hydrogel of claim 2 , wherein the mucoadhesive polypeptide is selected from the group consisting of: trefoil factor 1 (TFF1), trefoil factor 2 (TFF2), trefoil factor 3 (TFF3), and a microbial anti-inflammatory molecule (MAM) domain. 4. The biologic hydrogel of claim 1 , wherein CsgA fusion protein comprises a linker polypeptide linker sequence adjoining the CsgA polypeptide and the activity polypeptide. 5. The biologic hydrogel of claim 1 , wherein the engineered CsgA fusion protein further comprises a polypeptide tag selected from the group consisting of a poly-histidine tag, a myc tag, a FLAG tag, a hemagglutinin (HA) tag, and a V5 tag. 6. The biologic hydrogel of claim 1 , comprising a cell, wherein the cell is a bacterial cell, a mammalian cell, a protozoan, or a fungus. 7. The biologic hydrogel of claim 6 , wherein the cell is a bacterial cell, and wherein the bacterial cell comprises a heterologous nucleic acid, which comprises a heterologous gene encoding the engineered CsgA fusion, or wherein the bacterial cell comprises a heterologous nucleic acid, which comprises a heterologous gene encoding a polypeptide selected from the group consisting of an extracellular matrix component, a therapeutic polypeptide, a mucoadhesive polypeptide, a cytokine, an enzyme, an antibody, or an antibody mimetic sequence. 8. The biologic hydrogel of claim 1 , wherein the hydrogel comprises a nucleic acid, an extracellular matrix component, a polysaccharide, a metabolite, a metal ion, a nanoparticle, a polypeptide, cellulose, a vitamin, a nutraceutical, or a detectable compound. 9. The biologic hydrogel of claim 1 , wherein the biologic hydrogel is suitable for use in an application selected from the group consisting of: biocatalysis, chemical production, filtration, isolation of molecules from an aqueous solution, water filtration, bioremediation, nanoparticle synthesis, nanowire synthesis, display of optically active materials, surface coating, structural reinforcement of an object, and delivery of a therapeutic agent, or wherein the biologic hydrogel is suitable for use as a therapeutic biomaterial, a biological scaffold, a delivery system for therapeutic agents, a biosensor, a biocatalyst, a coating, and an electronically conductive material. 10. A particle comprising the biologic hydrogel of claim 1 . 11. A pharmaceutical composition comprising the biologic hydrogel of claim 1 , and a pharmaceutically-acceptable excipient. 12. The biologic hydrogel of claim 1 , wherein the hydrogel comprises at least 5% (w/w) curli fiber. 13. The biologic hydrogel of claim 12 , wherein the hydrogel comprises at least 10% (w/w) curli fiber.
Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence) · CPC title
semi-solid, gel, hydrogel, ointment · CPC title
Culture media for cell or tissue culture (media for specific animal cell type C12N5/06) · CPC title
Nanotechnology for materials or surface science, e.g. nanocomposites · CPC title
Alzheimer's disease; Amyloid plaque core protein · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.